Knight Therapeutics | GUD - Gross Profit On Sales

Stock Price
8.28
Daily Change
-0.15 -1.78%
Monthly
9.81%
Yearly
43.50%
Q2 Forecast
8.25

Knight Therapeutics reported CAD64.72M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 21.47M 434K Dec/2025
Cronos Group USD 16.19M 34.52M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
IQVIA Holdings USD 1.07B 52M Mar/2026
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD -566M 792M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Organigram Holdings CAD 23.32M 8.52M Dec/2025
Organon & Co USD 854M 3M Dec/2025
Revvity USD 387.66M 34M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.38B 229.9M Mar/2026
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025